Western blotting: principles, applications, and techniques
30 min
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Research interviews
-
18 min
1. Advancing ALS genetics through accessible testing- Dr. Teresa Fecteau
-
2. Nociceptor-macrophage crosstalk in endometriosis: insights into pain and disease progression- Dr. Michael S. Rogers
-
14 min
3. Pioneering proteomics: insights on advancements in the science of proteins- Prof. Ruedi Aebersold
-
19 min
4. The state of the art in secondary pharmacology- Dr. Jean-Pierre Valentin
-
18 min
5. How liver X receptor regulates intestinal regeneration and tumor growth- Dr. Srustidhar Das
-
11 min
-
14 min
7. Using real-world insights on drug interactions to inform drug development- Dr. Amita Datta-Mannan
-
21 min
8. The role of preregistration and registered reports in improving research transparency and reproducibility- Dr. Peter Bonde Ernst-Rasmussen
-
17 min
9. Decoding aging: how a proteomic clock predicts mortality and disease across populations- Dr. M. Austin Argentieri
-
14 min
10. Role of ETS2 in autoimmune and inflammatory diseases- Dr. James Lee
-
17 min
11. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD- Prof. Katrin Andreasson
-
19 min
12. The safety, toxicology, and regulation of antibody-drug conjugates- Dr. Veysel Kayser
-
13 min
13. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
18 min
-
18 min
15. Cancer vaccines- Dr. Elias Sayour
-
13 min
16. The regulation of cell therapy- Prof. Moutih Rafei
-
17 min
17. How and why neurons die in Alzheimer's disease?- Prof. Bart De Strooper
-
11 min
18. The future of blood tests in cancer treatment- Dr. Isaac Garcia-Murillas
-
50 min
19. Role of marketing authorization holder in drug safety- Dr. Raphael Elmadjian Pareschi
-
25 min
20. Synthetic whole embryo models and their applications- Prof. Jacob (Yaqub) Hanna
-
31 min
21. Scale-up challenges in the production of nanomedicines from lab to industry- Prof. Dr. Oya Tagit
-
14 min
22. Artificial intelligence in precision medicine- Dr. Michael P. Menden
-
30 min
23. Translational medicine: the risk of failure in delay and how to reduce it- Prof. Martin Wehling
-
8 min
24. Challenges and solutions of scaling up- Dr. Shaukat Ali
-
15 min
-
31 min
26. Management of generic drug development: challenges and opportunities- Mr. Sandeep Patil
-
10 min
27. MassBank development and future- Dr. Emma L. Schymanski
-
31 min
28. Elite controllers of HIV: from discovery to future therapies- Prof. Bruce Walker
-
25 min
29. Translational research in amyotrophic lateral sclerosis (ALS)- Prof. Aaron D. Gitler
-
29 min
30. Rheumatic diseases and musculoskeletal pain- Prof. Anisur Rahman
-
23 min
31. Towards developing a universal influenza vaccine- Prof. Peter Palese
- Clinical interviews
-
19 min
32. Predicting asthma exacerbations using machine learning models- Dr. Nestor Molfino
-
25 min
33. PANDAS: a potential link between group A streptococcal infections and neurological disorders- Prof. P. Patrick Cleary
-
10 min
-
17 min
35. Artificial intelligence in guiding cancer treatment decisions- Prof. Eytan Ruppin
-
6 min
36. Characterizing barriers to care in migraine- Prof. Dawn C. Buse
-
21 min
37. Monkeypox: etiopathogenesis, prevention, and treatments- Dr. Dennis Hruby
-
7 min
-
13 min
39. Kidney xenotransplantation- Dr. Douglas J. Anderson
-
28 min
40. CAR-T and TCR-T cellular immunotherapies in oncology- Prof. Sebastian Kobold
-
28 min
41. MAPS: the business of medical affairs- Dr. Danie du Plessis
-
26 min
42. Hypertrophic cardiomyopathy: therapies and treatments- Prof. Srihari Naidu
-
24 min
43. Combating the HIV epidemic- Prof. William Blattner
-
17 min
44. Epigenetic pharmaceuticals used in the clinic- Dr. Thomas Paul
-
21 min
45. Precision cancer medicine: development and future- Prof. Maurie Markman
-
31 min
46. Pediatric cancer testing- Prof. Joshua Schiffman
-
27 min
47. Opposition to vaccination: a transatlantic discussion- Prof. Jonathan Temte
-
26 min
48. Elective caesarean sections from an evolutionary perspective- Prof. Wenda Trevathan
-
19 min
49. Antiphospholipid syndrome and Lupus- Prof. Graham Hughes
-
16 min
50. Prescribing medications to children - a GP’s view- Dr. Amanda Simmons
- Annual Interviews
-
51. Antigen-specific immunotherapy for autoimmune diseases (ASIT)- Prof. David Cameron Wraith
-
52. Recent key advancements on mechanotransduction in cardiovascular health- Prof. Martin A. Schwartz
Topics Covered
- What is secondary pharmacology and why is it important?
- The International Consortium for Innovation and Quality in Pharmaceutical Development
- Key insights from the DruSafe survey
- Insights on current practice in secondary pharmacology and the consortium’s recommendations
- Challenges and opportunities in the field
Biography
Dr. Jean-Pierre Valentin is a scientist with over 30 years of experience in the pharmaceutical industry, specializing in drug discovery, safety pharmacology, and investigative toxicology. He earned his Ph.D. in Physiology and Pharmacology from the University of Montpellier, France, followed by postdoctoral research at the University of California, San Francisco.
Dr. Valentin began his career at the Pierre Fabre Research Centre, contributing to the discovery and development of three drug candidates. He later joined AstraZeneca, where he established and led the Department of Safety Pharmacology, supporting the safety assessment of approximately 200 candidate drugs across multiple therapeutic areas. His work contributed to the development and registration of several marketed products.
In 2014, he joined UCB-Biopharma as Senior Director and Head of Investigative Toxicology, overseeing safety science across the company’s portfolio and modalities.
He is a former President of the Safety Pharmacology Society and serves as co-chair of both the HESI Proarrhythmia Subcommittee and the HESI Cardiac Steering Team. He is also a member of the Board of Trustees and Executive Committee of HESI, Chair of the IQ-DruSafe Secondary Pharmacology Working Group, and EFPIA representative on the ICH E14-S7B committee.
Dr. Valentin is actively involved in education and mentoring through scientific societies, universities, and industry associations. He has authored or co-authored several patents and over 250 peer-reviewed publications and book chapters.
Links
Series:
Categories:
External Links
Talk Citation
Valentin, J. (2025, July 31). The state of the art in secondary pharmacology [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved August 14, 2025, from https://doi.org/10.69645/CELX5395.Export Citation (RIS)
Publication History
- Published on July 31, 2025
Financial Disclosures
- Dr. Jean-Pierre Valentin has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
The state of the art in secondary pharmacology
Published on July 31, 2025
19 min
A selection of talks on Methods
Transcript
Please wait while the transcript is being prepared...